CXCL4/CXCR3 axis regulates cardiac fibrosis by activating TGF-β1/Smad2/3 signaling in mouse viral myocarditis

BackgroundSevere myocarditis is often accompanied by cardiac fibrosis, but the underlying mechanism has not been fully elucidated. CXCL4 is a chemokine that has been reported to have pro-inflammatory and profibrotic functions. The exact role of CXCL4 in cardiac fibrosis remains unclear.MethodsViral myocarditis (VMC) models were induced by intraperitoneal injection of Coxsackie B Type 3 (CVB3). In vivo, CVB3 (100 TCID50) and CVB3-AMG487 (CVB3: 100 TCID50; AMG487: 5 mg/kg) combination were administered in the VMC and VMC+AMG487 groups, respectively. Hematoxylin and eosin staining, severity score, Masson staining, and immunofluorescence staining were performed to measure myocardial morphology in VMC. Enzyme-linked immunosorbent assay (ELISA) and quantitative reverse transcription polymerase chain reaction (qRT-PCR) were performed to quantify inflammatory factors (IL-1 beta, IL-6, TNF-alpha, and CXCL4). Aspartate aminotransferase (AST), lactate dehydrogenase (LDH), and creatine kinase-myocardial band (CK-MB) levels were analyzed by commercial kits. CXCL4, CXCR3B, alpha-SMA, TGF-beta 1, Collagen I, and Collagen III were determined by Western blot and immunofluorescence staining.ResultsIn vivo, CVB3-AMG487 reduced cardiac injury, alpha-SMA, Collagen I and Collagen III levels, and collagen deposition in VMC+AMG487 group. Additionally, compared with VMC group, VMC+AMG group decreased the levels of inflammatory factors (IL-1 beta, IL-6, and TNF-alpha). In vitro, CXCL4/CXCR3B axis activation TGF-beta 1/Smad2/3 pathway promote mice cardiac fibroblasts differentiation.ConclusionCXCL4 acts as a profibrotic factor in TGF-beta 1/Smad2/3 pathway-induced cardiac fibroblast activation and ECM synthesis, and eventually progresses to cardiac fibrosis. Therefore, our findings revealed the role of CXCL4 in VMC and unveiled its underlying mechanism. CXCL4 appears to be a potential target for the treatment of VMC. CXCL4 promotes cardiac fibrosis through activating the TGF-beta 1/Smad2/3 signaling pathway. Inhibition of CXCL4 secretion may be considered a potential therapeutic target for myocarditis treatment. image